Adalimumab for early Vogt-Koyanagi-Harada eye inflammation
Treatments studied
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial studies adalimumab to treat a rare, fast-onset eye inflammation called Vogt-Koyanagi-Harada disease. It may help people who can’t use strong steroid treatments or whose disease is not improving quickly with them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 70 years old
- You must not have active or past hidden tuberculosis (TB)
- Your Vogt-Koyanagi-Harada symptoms must have started less than 1 month ago
- You must have taken strong steroid pills through the body for less than 1 week before starting
- You must not be able to use steroids long-term, or you have another major reason steroids limited your care, or steroids didn’t lead to enough eye repair after 1 week
- You must not have an infection-related eye inflammation (for example TB, CMV, herpes viruses, Lyme, or toxoplasmosis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies giving immune-suppressing treatment early in Vogt-Koyanagi-Harada (VKH) disease to see if it improves outcomes. It may help people reduce ongoing eye inflammation if they qualify and can be followed for a longer time.
This study tests an injection called adalimumab (Tebiovio®) to see if it helps control inflammation in the eyes of adults with non-infectious uveitis. It might be a good option if you are already on steroid pills and looking for another treatment.
This trial studies whether adalimumab (an immune medicine) added to a medium-dose steroid improves eye inflammation from refractory Behçet’s disease that keeps coming back. It also checks safety to see if the benefits outweigh risks.
This trial tests a combination of two medications (adalimumab and mycophenolate mofetil) to reduce eye inflammation in people with uveitis that requires steroids. It aims to help patients use less steroid medication while keeping their uveitis under control.
This trial compares two forms of the same medicine (adalimumab) to treat non-infectious uveitis, an inflammation inside the eye. It aims to see which delivery method works better to control active inflammation and protect vision.
This study compares two medicines—adalimumab and tocilizumab—to see which works better and is safer for severe “uveitis” in people with Behçet’s disease. It’s meant for adults whose eye inflammation threatens their sight.
Hear when a new Vogt-Koyanagi-Harada Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.